Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2019-03-13 Declaration of Voting R…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It details changes in voting rights percentages (crossing thresholds) held by a shareholder (The Goldman Sachs Group, Inc. and its subsidiaries) in Evotec AG, referencing specific dates and share counts. This content directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification category.
2019-03-13 English
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
Report Publication Announcement Classification · 99% confidence The document is a short press release dated March 7, 2019, announcing that Evotec AG management will be presenting at several upcoming investor conferences (BioCapital Europe, Bankhaus Lampe Deutschlandkonferenz, H.C. Wainwright Global Life Sciences Conference, Kempen & Co Life Sciences Conference). This type of announcement, detailing attendance at investor events rather than releasing financial results or mandatory regulatory reports, is best classified as a general Investor Presentation or related communication. However, none of the specific codes perfectly match 'Investor Conference Attendance Announcement'. Reviewing the definitions: - ER (Earnings Release): No financial results. - IP (Investor Presentation): This is close, as it relates to investor engagement, but it's an announcement *about* future presentations, not the presentation itself. - RPA (Report Publication Announcement): This is for announcing the publication of a formal report (like a 10-K or IR), which this is not. - RNS (Regulatory Filings): This is the general fallback for miscellaneous corporate news that doesn't fit elsewhere. Since the content is purely logistical information about management attending external industry/investor events, and it lacks the substance of a formal report (10-K, IR, ER, IP), RNS is the most appropriate catch-all category for this type of corporate update distributed via DGAP News Service.
2019-03-07 English
Evotec AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Evotec AG: Release according to Article 41 of the WpHG' and specifically announces the 'Publication of total number of voting rights' following a 'Conditional capital increase'. This relates directly to changes in the company's capital structure and voting rights, which falls under Capital/Financing Update (CAP) or potentially Declaration of Voting Results & Voting Rights Announcements (DVA). However, the core subject is the capital measure (conditional capital increase) leading to a new total number of voting rights, which is a financing/capital structure event. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit for announcing the result of a capital increase affecting voting rights, although DVA is also related to voting rights. Since it explicitly details a capital measure (increase), CAP is prioritized over DVA, which usually reports the *results* of a vote, not the structural change itself. The document is a formal regulatory announcement (DGAP service) detailing a structural change.
2019-02-28 English
EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF SECOND PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER
Legal Proceedings Report Classification · 99% confidence The document is a press release dated February 28, 2019, announcing that Evotec AG received a milestone payment from Bayer because a drug candidate advanced into Phase II clinical trials for persistent chronic cough. This type of announcement, detailing specific operational achievements, partnership progress, and associated payments, is characteristic of an Earnings Release (ER) or a general corporate news update. Since it focuses on a specific, material operational event (milestone payment and trial advancement) rather than a comprehensive financial overview (10-K or IR) or a general regulatory filing (RNS), the most appropriate classification is Earnings Release (ER), as these often contain key operational highlights that drive earnings expectations. It is not a transcript (CT), a formal annual report (10-K), or a dividend notice (DIV). Given the nature of the announcement being a key operational update, ER is the best fit among the provided options, although it could also be considered RNS if no other category fit well. However, milestone payments are frequently highlighted in ERs.
2019-02-28 English
Präsentation FY 2018
Investor Presentation Classification · 98% confidence The document text is structured like a presentation, containing slides with titles such as 'Highlights & strategy review', 'Financial performance 2018', 'Guidance 2019 and next steps', and detailed tables summarizing financial results (Revenues, Adjusted Group EBITDA) for 2018 and Q4 2018, along with strategic updates. The content is clearly designed to inform investors about past performance and future outlook, which is characteristic of an Investor Presentation (IP) or potentially an Earnings Release (ER) if it were shorter and focused only on highlights. Given the depth of financial tables, segment breakdowns, and strategic narrative presented in a slide format, 'Investor Presentation' (IP) is the most appropriate classification. It is not a full Annual Report (10-K) or a standalone Audit Report (AR). It is too detailed to be just a Report Publication Announcement (RPA).
2019-02-28 English
EVOTEC AND HELMHOLTZ CENTRE JOINING PLATFORMS AND FORCES FOR NOVEL ANTIBIOTICS
Legal Proceedings Report Classification · 99% confidence The document is a press release dated February 20, 2019, announcing a collaboration between Evotec AG and the Helmholtz Centre for Infection Research regarding the development of novel antibiotics. It is structured as a news item, includes quotes from management, and details a business development/research partnership. This type of announcement, which details strategic business activities but is not a formal financial report (like 10-K, IR, or ER), typically falls under general corporate news or regulatory announcements. Since it is not a specific financial filing, management change, dividend notice, or capital event, the most appropriate general category for a significant, non-financial corporate update disseminated via a news service (DGAP) is 'Regulatory Filings' (RNS) as a catch-all for important, non-standardized corporate news, or potentially 'LTR' if it were a legal matter, but here it is a partnership announcement. Given the options, RNS serves as the best fit for a general corporate news release about a strategic collaboration that doesn't match the other specific codes.
2019-02-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.